Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery

Sarika Sabnis, Nirupama A. Sabnis, Sangram Limbaji Raut, Andras G. Lacko

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Current cancer chemotherapy is frequently associated with short- and long-term side effects, affecting the quality of life of cancer survivors. Because malignant cells are known to overexpress specific surface antigens, including receptors, targeted drug delivery is often utilized to reduce or overcome side effects. The current study involves a novel targeting approach using specifically designed nanoparticles, including encapsulation of the anti-cancer drug valrubicin into superparamagnetic iron oxide nanoparticle (SPION) containing reconstituted high-density lipoprotein (rHDL) nanoparticles. Specifically, rHDL-SPION-valrubicin hybrid nanoparticles were assembled and characterized with respect to their physical and chemical properties, drug entrapment efficiency and receptor-mediated release of the drug valrubicin from the nanoparticles to prostate cancer (PC-3) cells. Prussian blue staining was used to assess nanoparticle movement in a magnetic field. Measurements of cytotoxicity toward PC-3 cells showed that rHDL-SPION-valrubicin nanoparticles were up to 4.6 and 31 times more effective at the respective valrubicin concentrations of 42.4 µg/mL and 85 µg/mL than the drug valrubicin alone. These studies showed, for the first time, that lipoprotein drug delivery enhanced via magnetic targeting could be an effective chemotherapeutic strategy for prostate cancer.

Original languageEnglish
Pages (from-to)1453-1464
Number of pages12
JournalInternational Journal of Nanomedicine
Volume12
DOIs
StatePublished - 22 Feb 2017

Fingerprint

valrubicin
Lipoproteins
HDL Lipoproteins
Drug delivery
Nanoparticles
Pharmaceutical Preparations
Iron oxides
Prostatic Neoplasms
Neoplasms
Antigen Receptors
Chemotherapy
Magnetic Fields
Surface Antigens
Antigens
Cytotoxicity
Encapsulation
Chemical properties
Survivors
Physical properties
Quality of Life

Keywords

  • Drug delivery
  • Magnetic nanoparticles
  • Nanoparticles
  • SPION
  • rHDL

Cite this

@article{802972142acd4cd393fb2023986b4482,
title = "Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery",
abstract = "Current cancer chemotherapy is frequently associated with short- and long-term side effects, affecting the quality of life of cancer survivors. Because malignant cells are known to overexpress specific surface antigens, including receptors, targeted drug delivery is often utilized to reduce or overcome side effects. The current study involves a novel targeting approach using specifically designed nanoparticles, including encapsulation of the anti-cancer drug valrubicin into superparamagnetic iron oxide nanoparticle (SPION) containing reconstituted high-density lipoprotein (rHDL) nanoparticles. Specifically, rHDL-SPION-valrubicin hybrid nanoparticles were assembled and characterized with respect to their physical and chemical properties, drug entrapment efficiency and receptor-mediated release of the drug valrubicin from the nanoparticles to prostate cancer (PC-3) cells. Prussian blue staining was used to assess nanoparticle movement in a magnetic field. Measurements of cytotoxicity toward PC-3 cells showed that rHDL-SPION-valrubicin nanoparticles were up to 4.6 and 31 times more effective at the respective valrubicin concentrations of 42.4 µg/mL and 85 µg/mL than the drug valrubicin alone. These studies showed, for the first time, that lipoprotein drug delivery enhanced via magnetic targeting could be an effective chemotherapeutic strategy for prostate cancer.",
keywords = "Drug delivery, Magnetic nanoparticles, Nanoparticles, SPION, rHDL",
author = "Sarika Sabnis and Sabnis, {Nirupama A.} and Raut, {Sangram Limbaji} and Lacko, {Andras G.}",
year = "2017",
month = "2",
day = "22",
doi = "10.2147/IJN.S122036",
language = "English",
volume = "12",
pages = "1453--1464",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery. / Sabnis, Sarika; Sabnis, Nirupama A.; Raut, Sangram Limbaji; Lacko, Andras G.

In: International Journal of Nanomedicine, Vol. 12, 22.02.2017, p. 1453-1464.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery

AU - Sabnis, Sarika

AU - Sabnis, Nirupama A.

AU - Raut, Sangram Limbaji

AU - Lacko, Andras G.

PY - 2017/2/22

Y1 - 2017/2/22

N2 - Current cancer chemotherapy is frequently associated with short- and long-term side effects, affecting the quality of life of cancer survivors. Because malignant cells are known to overexpress specific surface antigens, including receptors, targeted drug delivery is often utilized to reduce or overcome side effects. The current study involves a novel targeting approach using specifically designed nanoparticles, including encapsulation of the anti-cancer drug valrubicin into superparamagnetic iron oxide nanoparticle (SPION) containing reconstituted high-density lipoprotein (rHDL) nanoparticles. Specifically, rHDL-SPION-valrubicin hybrid nanoparticles were assembled and characterized with respect to their physical and chemical properties, drug entrapment efficiency and receptor-mediated release of the drug valrubicin from the nanoparticles to prostate cancer (PC-3) cells. Prussian blue staining was used to assess nanoparticle movement in a magnetic field. Measurements of cytotoxicity toward PC-3 cells showed that rHDL-SPION-valrubicin nanoparticles were up to 4.6 and 31 times more effective at the respective valrubicin concentrations of 42.4 µg/mL and 85 µg/mL than the drug valrubicin alone. These studies showed, for the first time, that lipoprotein drug delivery enhanced via magnetic targeting could be an effective chemotherapeutic strategy for prostate cancer.

AB - Current cancer chemotherapy is frequently associated with short- and long-term side effects, affecting the quality of life of cancer survivors. Because malignant cells are known to overexpress specific surface antigens, including receptors, targeted drug delivery is often utilized to reduce or overcome side effects. The current study involves a novel targeting approach using specifically designed nanoparticles, including encapsulation of the anti-cancer drug valrubicin into superparamagnetic iron oxide nanoparticle (SPION) containing reconstituted high-density lipoprotein (rHDL) nanoparticles. Specifically, rHDL-SPION-valrubicin hybrid nanoparticles were assembled and characterized with respect to their physical and chemical properties, drug entrapment efficiency and receptor-mediated release of the drug valrubicin from the nanoparticles to prostate cancer (PC-3) cells. Prussian blue staining was used to assess nanoparticle movement in a magnetic field. Measurements of cytotoxicity toward PC-3 cells showed that rHDL-SPION-valrubicin nanoparticles were up to 4.6 and 31 times more effective at the respective valrubicin concentrations of 42.4 µg/mL and 85 µg/mL than the drug valrubicin alone. These studies showed, for the first time, that lipoprotein drug delivery enhanced via magnetic targeting could be an effective chemotherapeutic strategy for prostate cancer.

KW - Drug delivery

KW - Magnetic nanoparticles

KW - Nanoparticles

KW - SPION

KW - rHDL

UR - http://www.scopus.com/inward/record.url?scp=85014341902&partnerID=8YFLogxK

U2 - 10.2147/IJN.S122036

DO - 10.2147/IJN.S122036

M3 - Article

VL - 12

SP - 1453

EP - 1464

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -